Blinded Consumer Study for the Evaluation of the Usability and Efficacy of One Medical Device in Venous Return

The primary goal of this study was to assess, in vivo, the efficacy of the medical device Invisible insoles LIGHT LEGS in improving venous return in subjects affected by this problem after 14 days of medical device use, by self-assessment, filling in questions regarding Quality of Life, in comparison to the baseline.

The secondary goals of this study were (1) to assess in vivo the perception of subjects about the rapid relief felt after 7 days of using the same medical device, by selfassessment, filling-in three subjective evaluation questions, and (2) to assess in vivo the usability of the subjects regarding the same medical device after 14 days of its use, by self-assessment, filling in subjective evaluation questions.

Study Overview

• Status: Completed
• Conditions: Quality of Life; Symptoms and Signs; Venous Disease
• Intervention / Treatment: Device: Insoles

• Study Type: Interventional
• Enrollment (Actual): 54
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Portugal
  • Porto, Portugal
    • Juliana Gouveia

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Gender: Female/Male;
• Age: with 18 years old and older;
• Having signed an Informed Consent Form (ICF);
• Willingness, ability and likeliness to comply with all the study procedures and restrictions;
• Ability to give informed consent;
• Available during the entire study period;
• Understanding Portuguese language: Portuguese-speaking subjects capable of reading the documents;
• Affected by a symptomatic venous return problem;
• With a score >14 from the question 1 to 11 of the adapted CIVIQ questionnaire (each question scored on a scale from 0 to 4);
• Agree to wear open shoes suitable for insoles throughout the study, for at least 8 hours per day (with a heel <5cm);
• Having a shoe size of 36 to 41;

Exclusion Criteria:

• Known allergy or known history of hypersensitivity to the components of the investigational device and related compounds;
• Currently participating in another clinical study that may interfere with the study;
• Diagnosed skin diseases and/or cutaneous alterations on the test region (feet) that may impair the study (for example tattoos, marks, burns, scars, etc.);
• Diagnosed diseases that may impair the study (including but not limited to: Diabetes, Arteritis, Phlebitis, etc);
• Under pharmacological treatments on the 30 days previous to the beginning of the study and during the entire period of the study that may impair it (including but not limited to: inflammatory drugs, any drug that might cover the signs and symptoms, drugs with arterial or venous indications, etc.);
• Having applied any type of topical product (pharmaceutical, cosmetic or other) with similar effect of the medical device under study, on the test region (feet) during the study, besides the investigational device;
• Having a stage of CVD C3 on the CEAP classification;
• Having had a traumatic or neurological history in the last 6 months;
• Wearing an orthopaedic insole made by a health professional;
• Having a significant and disabling lower limb pain;
• Having a significant and disabling back pain;
• Having a contraindication to wearing insoles and open shoes;
• Wearing open shoes with an anatomical shape (e.g. Birkenstock);
• Pregnancy or intention to conceive during the study;
• Breast-feeding.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental: One medical device as investigational device	Device: Insoles; Insoles At Day 0, the patient received the insoles and adapted them to his open shoes. The patient filled the quality-of-life's questionnaire at Day 0 and the same at Day14. The patient filled the rapid relief's questionnaire at Day7 and a usability's questionnaire at Day14.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quality of Life	CIVIQ (ChronIc Venous Insufficiency Quality of Life Questionnaire) 20 : It is a quality of life assessment scale comprising 20 items grouped into four main dimensions (pain, physical, psychological, social) with 5 levels (0 point (min) to 4 points (max)).The final score is between 0 and 80 points. A low score indicates a low impact of the disease on quality of life.	Day 0 and Day 14

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rapid relief	Perception of subjects about the rapid relief felt after 7 days (t7) of using the medical device, by self-assessment, filling-in three subjective evaluation questions	Day 7
Usability evaluation	Usability of the subjects regarding the same device, through subjective evaluation questions filled by the subjects after 14 days (D14) of using the medical device.	Day 14

Collaborators and Investigators

• Sponsor: Millet Innovation

Study record dates

Study Major Dates

• Study Start (Actual): August 5, 2025
• Primary Completion (Actual): September 11, 2025
• Study Completion (Actual): September 11, 2025

Study Registration Dates

• First Submitted: November 14, 2025
• First Submitted That Met QC Criteria: November 14, 2025
• First Posted (Actual): November 18, 2025

Study Record Updates

• Last Update Posted (Actual): November 18, 2025
• Last Update Submitted That Met QC Criteria: November 14, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Keywords: quality of life; symptoms; relief; insoles; Chronic venous disease
• Additional Relevant MeSH Terms: Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Orthopedic Equipment; Surgical Equipment; Equipment and Supplies; Orthotic Devices; Foot Orthoses
• Other Study ID Numbers: P023B24

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No